Viral vector-based cell therapy uses modified viruses to deliver a healthy gene into a cell to treat a disease. The Read More
Merck agrees to buy Mirus Bio for $600M to go deeper into viral vector manufacturing
Vator · eNuvio co-founder Mark Aurousseau and Mirus Bio COO Geoff Schwartz on the VatorNews podcast On the Read More